Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

被引：1

作者：

Kaplan, David ^{[1
]}

Husni, Elaine ^{[2
]}

Chang, Eunice ^{[3
]}

S. Broder, Michael ^{[3
]}

Paydar, Caleb ^{[3
]}

Bognar, Kata ^{[3
]}

Yan, Jessie ^{[4
]}

Richter, Sven ^{[5
]}

Desai, Pooja ^{[6
]}

Khilfeh, Ibrahim ^{[7
]}

机构：

[1] Adult & Pediat Dermatol, Overland Pk, KS 66211 USA

[2] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH 44195 USA

[3] Partnership Hlth Analyt Res LLC, Beverly Hills, CA 90212 USA

[4] Roche, San Francisco, CA 94080 USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Janssen Pharmaceut, Titusville, NJ 08560 USA

[7] Janssen Pharmaceut, Raritan, NJ 08869 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2022年 / 11卷 / 08期

关键词：

administrative claims analysis; biologic initiation; DMARD; oral small molecules; PLAQUE PSORIASIS; ARTHRITIS; EFFICACY; CARE; PREDICTORS; MANAGEMENT; MODERATE; SAFETY; AGE;

D O I：

10.2217/cer-2021-0311

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). Methods: This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. Outcomes: Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. Results: APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37-0.48; p < 0.001), lower adjusted biologic initiation rate (14.4% [95% CI: 13.2-15.7%] vs 28.6% [95% CI: 26.8-30.5%]), lower risk of biologic initiation (hazard ratio: 0.45; 95% CI: 0.40-0.51; p < 0.001) compared with MTX initiators. Conclusion: Systemic-naive patients with PsO have a lower rate of biologic initiation over 1 year following APR initiation.

引用

页码：575 / 582

页数：8

共 50 条

[41] Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study
Kim, Hyunho
Lee, Seung-Hwan
Kim, Dong Hwan
Lee, Ji Youl
Hong, Sung-Hoo
Ha, U-Syn
Kim, In-Ho
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (05) : 2113 - 2121
[42] Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy
Sukasema, Chonlaphat
Churdboonchart, Vina
Sukeepaisarncharoen, Wisut
Piroj, Wantanich
Inwisai, Tasanee
Tiensuwan, Montip
Chantratita, Wasun
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 (03) : 277 - 281
[43] Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data
Peterson, Rosemary G.
Xiao, Rui
Katcoff, Hannah
Fisher, Brian T.
Weiss, Pamela F.
PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)
[44] Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data
Rosemary G. Peterson
Rui Xiao
Hannah Katcoff
Brian T. Fisher
Pamela F. Weiss
Pediatric Rheumatology, 19
[45] Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)
Gomez-Ayerbe, Cristina
Palacios, Rosario
Mayorga, Marisa
Nicolas Navarrete, Miguel
Ferra, Sergio
Ruiz, Inmaculada
Garcia, Coral
Castano, Manuel
Merino, Dolores
Collado, Antonio
Hidalgo-Tenorio, Carmen
Delgado, Marcial
Rivero, Antonio
Santos, Jesus
INTERNATIONAL JOURNAL OF STD & AIDS, 2022, 33 (13) : 1119 - 1123
[46] Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
Chin, Ken Lee
Ofori-Asenso, Richard
Si, Si
Hird, Thomas R.
Magliano, Dianna J.
Zoungas, Sophia
Liew, Danny
SCIENTIFIC REPORTS, 2019, 9 (1)
[47] Bictegravir/Emtricitavine/ Tenofovir alafenamide as first-line treatment in naive HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial
Hidalgo-Tenorio, C.
Sequera, S.
Collado, A.
Vinuesa, D.
Vivancos, M. J.
De Los Santos, I.
Sorni, P.
Cabello, N.
Montero, M.
Terron, A.
Martinez, O.
Omar-Mohamed, M.
Ryan, P.
Galindo, M. J.
Pasquau, J.
Javier, R.
Lopez Ruz, M. A.
HIV MEDICINE, 2023, 24 : 212 - 212
[48] Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
Ken Lee Chin
Richard Ofori-Asenso
Si Si
Thomas R. Hird
Dianna J. Magliano
Sophia Zoungas
Danny Liew
Scientific Reports, 9
[49] Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients with Rheumatoid Arthritis
Pappas, Dimitrios
O'Brien, Jacqueline
Guo, Lin
Shan, Ying
Baker, Joshua
Kricorian, Greg
Stryker, Scott
Collier, David
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3142 - 3145
[50] REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA
Kossack, N.
Schoenfelder, T.
Schultze, M.
Pignot, M.
Mehta, S.
Nazareth, T.
Walzer, S.
VALUE IN HEALTH, 2019, 22 : S904 - S904

← 1 2 3 4 5 →